Who
Laura Hamill
Director
Company insider
Files Form 4 as: Director, Jazz Pharmaceuticals; Director, Fate Therapeutics; Director, Y-mAbs Therapeutics; Director, Pardes Biosciences; Director, Scilex Holding; Director, AnaptysBio; Director, Acceleron Pharma; EVP, Worldwide Commercial Ops, Gilead Sciences.
In numbers
- Trades disclosed
- 55
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 8
- Companies where not an officer
- 7
- First trade
- 7 Oct 2018
- Last trade
- 31 Aug 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 2 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $3,41714 at $244.06 | filing |
| 31 Aug 2026filed 2 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $408K1,692 at $241.39 | filing |
| 31 Aug 2026filed 2 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $3,41714 at $244.06 | filing |
| 31 Aug 2026filed 2 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $408K1,692 at $241.39 | filing |
| 5 Aug 2026filed 7 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —1,605 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —1,605 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,800 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,800 at $0.00 | filing |
| 16 Sep 2025filed 19 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —27,000 | filing |
| 16 Sep 2025filed 19 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —11,000 | filing |
| 16 Sep 2025filed 19 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —16,000 | filing |
| 16 Sep 2025filed 19 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —13,950 | filing |
| 16 Sep 2025filed 19 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —14,545 | filing |
| 16 Sep 2025filed 19 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —33,450 | filing |
| 16 Sep 2025filed 19 Sep 2025 | Y-mAbs Therapeutics | SEC FORM 4 Code U | $50K5,825 at $8.60 | filing |
| 16 Sep 2025filed 19 Sep 2025 | Y-mAbs Therapeutics | SEC FORM 4 Code D | —25,080 | filing |
| 8 Aug 2025filed 11 Aug 2025 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $201K1,805 at $111.25 | filing |
| 7 Aug 2025filed 11 Aug 2025 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —3,507 at $0.00 | filing |
| 30 Jun 2025filed 2 Jul 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code A | —33,450 at $0.00 | filing |
| 30 Jun 2025filed 2 Jul 2025 | Y-mAbs Therapeutics | SEC FORM 4 Code A | —25,080 at $0.00 | filing |
News
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertisemanilatimes.net · 6 Oct 2026
1 headline in the last 90 days name Laura Hamill; no company of theirs resolves to a name we track.
Sectors
No trade we could place in a sector.